An agentic system for rare disease diagnosis with traceable reasoning

Weike Zhao1,2,3, Chaoyi Wu1, Yanjie Fan4,5

  • 1School of Artificial Intelligence, Shanghai Jiao Tong University, Shanghai, China.

Nature
|February 18, 2026
PubMed

Insights

DeepRare, a novel multi-agent system, significantly improves rare disease diagnosis by integrating large language models and specialized tools. It aims to shorten the diagnostic odyssey for millions affected by rare conditions.

Area of Science:

  • Medical Informatics
  • Artificial Intelligence in Medicine
  • Genomics

Background:

  • Rare diseases impact over 300 million globally, presenting significant diagnostic challenges.
  • Patients face a lengthy 'diagnostic odyssey' with delays, misdiagnoses, and increased burdens.

Purpose of the Study:

  • To introduce DeepRare, a multi-agent system for rare disease differential diagnosis decision support.
  • To leverage large language models and specialized tools for enhanced diagnostic accuracy.

Main Methods:

  • DeepRare integrates over 40 specialized tools and knowledge sources.
  • It processes heterogeneous clinical data including free text, Human Phenotype Ontology (HPO) terms, and genetic results.
  • A multi-agent system powered by large language models generates ranked diagnostic hypotheses with transparent reasoning.

Main Results:

  • DeepRare demonstrated exceptional performance across 2,919 diseases in 14 medical specialties.
  • Achieved an average Recall@1 of 57.18% in HPO-based tasks, outperforming other methods by 23.79%.
  • In multi-modal tests, DeepRare reached 69.1% accuracy, surpassing Exomiser (55.9%). Expert review confirmed 95.4% agreement on reasoning validity.

Conclusions:

  • DeepRare significantly advances rare disease diagnosis by providing accurate, evidence-based diagnostic hypotheses.
  • The system demonstrates the potential of large-language-model-driven agentic systems to transform clinical workflows.
  • This approach promises to reduce the diagnostic odyssey and improve patient outcomes for rare diseases.

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.8K
Pedigree Analysis01:35

Pedigree Analysis

Overview
89.9K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
25
Classification of Illness01:17

Classification of Illness

The meaning of illness is individualized to each person who experiences an alteration in health. In contrast, disease is a medical term indicating a pathological change in the structure and function of the body or mind. It is a condition that has specific symptoms and boundaries.
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe...
8.9K